Intervention not reported
Mirtazapine standard dose RCTs: 1 Participants: 422 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Low
Intervention not reported
Duloxetine low dose RCTs: 6 Participants: 1116 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
6 participants
Moderate
Intervention not reported
Esreboxetine high dose RCTs: 1 Participants: 555 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
1 participants
Very low
Proportion of participants reporting no worse than mild pain by 14 days after start of treatment · adults with cancer‐related pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient Global Impression of Change much or very much improved · adults with cancer‐related pain
Cannabis‐based medicines probably leads to higher PGIC of much improved or very much improved compared with placebo medication (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in withdrawals due to adverse events compared with placebo medication (moderate certainty).
1 finding from 1 review
Mean pain intensity (Numeric Rating Scale 0–10) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in mean pain intensity (Numeric Rating Scale 0–10) compared with placebo medication (moderate certainty).
1 finding from 1 review
Daily maintenance opioid dosage (mg morphine equivalent) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in daily maintenance opioid dosage (mg morphine equivalent) compared with placebo medication (low certainty).
1 finding from 1 review
Daily breakthrough opioid dosage (mg morphine equivalent) · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in daily breakthrough opioid dosage (mg morphine equivalent) compared with placebo medication (moderate certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · adults with cancer‐related pain
Cannabis‐based medicines showed no clear difference in participants experiencing any serious adverse event compared with placebo medication (moderate certainty).
1 finding from 1 review
Outcome№ of participants(studies) · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Relief of pain · children with acute postoperative pain
2 findings from 1 review
no estimate extracted
50 participants
GRADE not reported
no estimate extracted
50 participants
GRADE not reported
Reduction in pain intensity · children with acute postoperative pain
2 findings from 1 review
no estimate extracted
0 participants
GRADE not reported
no estimate extracted
2 participants
GRADE not reported
Nausea and vomiting · children with acute postoperative pain
It is very uncertain whether diclofenac changes nausea, vomiting, or both during study period № of participants:… compared with placebo (very low certainty).
1 finding from 1 review
Any bleeding during study period № of participants: 100(2 RCTs)d · children with acute postoperative pain
It is very uncertain whether diclofenac changes any bleeding during study period № of participants: 100(2 RCTs)d compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events during the study period · children with acute postoperative pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer irrespective of whether receiving palliative care and with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Laxation response: patient assessment of change in bowel status at the end of trial · people with cancer and receiving palliative care with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found